Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

(P012) National Trends in Surgery for Sinonasal Malignancy: The Effect of Hospital Volume on Short-Term Outcomes

April 15, 2014
Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S
Conference|Annual Meeting of the American Radium Society (ARS)

Sinonasal carcinomas are rare, highly morbid neoplasms originating in the nasal cavity and paranasal sinuses. The mainstay of treatment over the past 2 decades has been a combination of surgery, radiation, and chemotherapy. We sought to characterize trends in the initial management of sinonasal malignancy with a particular focus on the impact of hospital volume on surgical care and outcomes.

David Ouyang, BS, Ivan El-Sayed, MD, Sue S. Yom, MD, PhD; Department of Radiation Oncology and Department of Otolaryngology-Head and Neck Surgery, University of California

Background: Sinonasal carcinomas are rare, highly morbid neoplasms originating in the nasal cavity and paranasal sinuses. The mainstay of treatment over the past 2 decades has been a combination of surgery, radiation, and chemotherapy. We sought to characterize trends in the initial management of sinonasal malignancy with a particular focus on the impact of hospital volume on surgical care and outcomes.

Methods: A retrospective cohort study was conducted, examining time trends among patients admitted for surgical resection of sinonasal malignancy in the National Inpatient Sample (NIS) between 1988 and 2009. Subset analysis of high-risk cases was performed on patient cohorts with skull base involvement or orbital or maxillary sinus involvement or those who underwent neck dissection. Patient characteristics as well as hospital attributes were correlated with patient morbidity and mortality.

Results: Over the course of 22 years, we identified 3,850 cases of sinonasal surgery patients from 879 hospitals-24.3% of patients had complications, ranging from infections, cardiopulmonary complications, neuropathy, visual disturbances, and electrolyte abnormalities, and 0.8% of hospitalizations resulted in mortality. High-risk cases with skull base or orbital or maxillary sinus involvement or including neck dissection had more complications (29.4% vs 23.2%; P < .001) and a longer length of stay (9.34 d vs 6.13 d, P < .001). There was an increase in the number of cases with neck dissection over the time period studied.

Thirty-two hospitals averaged more than five cases per year, accounting for 28% (1,097) of all sinonasal surgeries. These high-volume centers were predominantly large (73.3%), urban (96.7%), teaching (90%) institutions and performed more high-risk cases, accounting for 32.4% of cases, including neck dissection, 44.6% of cases with orbital involvement, and 43.1% of cases with skull base involvement. Compared with low-volume centers, high-volume centers had more cardiopulmonary complications (21.1% vs 17.8%; P = .024), electrolyte abnormalities (10.4% vs 7.2%; P = .018), and longer lengths of stay for both high-risk cases (10.58 d vs 8.59 d; P = .003) and non–high-risk cases (6.84 d vs 5.89 d; P = .004). Over the time period studied, a greater proportion of cases were recently performed at high-volume centers.

Conclusions: This study characterizes current trends in the initial management of sinonasal cancer. There is an increased likelihood that complicated surgeries are performed at higher-volume hospitals, which also entails a higher complication rate. High-risk cases resulted in higher rates of complications but were not associated with a higher mortality rate.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Recent Videos
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Better defining which patients with GI cancers are preferred candidates for adoptive cellular therapies may help optimize outcomes.
A consolidated database may allow providers to access information on a patient’s prior treatments and genetic abnormalities all in 1 place.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Related Content
Advertisement

We’re helping to train healthcare professionals from some of these countries, at least on the clinical side, and giving them an idea of how manufacturing happens.

How Are Cellular Therapeutics Distributed in Global Oncology Settings?

Tim Cortese
October 16th 2025
Article

In lower- and middle-income countries, accessibility, cost, and talent are obstacles to broadly implementing cellular therapeutics into cancer care.


Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.


Researching the feasibility of consolidating extensive information into a unified cancer database is the “tip of the iceberg”, said Leila Tchelebi, MD.

Comprehensive Cancer Database May Enhance Personalized Therapy

Russ Conroy
October 15th 2025
Article

Researching the feasibility of consolidating extensive information into a unified cancer database is the “tip of the iceberg”, said Leila Tchelebi, MD.


A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.


Trials slated for presentation at the 2025 ESMO Congress may reveal practice-changing data across different breast and lung cancer populations.

ESMO 2025: Key Anticipated Updates in Breast and Lung Tumors

Russ Conroy
October 13th 2025
Article

Trials slated for presentation at the 2025 ESMO Congress may reveal practice-changing data across different breast and lung cancer populations.


The addition of comprehensive bridging radiotherapy to extramedullary disease sites before CAR T therapy may improve PFS outcomes in multiple myeloma.

Bridging Radiotherapy Prior to CAR T May Be Safe in R/R Multiple Myeloma

Roman Fabbricatore
October 13th 2025
Article

The addition of comprehensive bridging radiotherapy to extramedullary disease sites before CAR T therapy may improve PFS outcomes in multiple myeloma.

Related Content
Advertisement

We’re helping to train healthcare professionals from some of these countries, at least on the clinical side, and giving them an idea of how manufacturing happens.

How Are Cellular Therapeutics Distributed in Global Oncology Settings?

Tim Cortese
October 16th 2025
Article

In lower- and middle-income countries, accessibility, cost, and talent are obstacles to broadly implementing cellular therapeutics into cancer care.


Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.


Researching the feasibility of consolidating extensive information into a unified cancer database is the “tip of the iceberg”, said Leila Tchelebi, MD.

Comprehensive Cancer Database May Enhance Personalized Therapy

Russ Conroy
October 15th 2025
Article

Researching the feasibility of consolidating extensive information into a unified cancer database is the “tip of the iceberg”, said Leila Tchelebi, MD.


A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.


Trials slated for presentation at the 2025 ESMO Congress may reveal practice-changing data across different breast and lung cancer populations.

ESMO 2025: Key Anticipated Updates in Breast and Lung Tumors

Russ Conroy
October 13th 2025
Article

Trials slated for presentation at the 2025 ESMO Congress may reveal practice-changing data across different breast and lung cancer populations.


The addition of comprehensive bridging radiotherapy to extramedullary disease sites before CAR T therapy may improve PFS outcomes in multiple myeloma.

Bridging Radiotherapy Prior to CAR T May Be Safe in R/R Multiple Myeloma

Roman Fabbricatore
October 13th 2025
Article

The addition of comprehensive bridging radiotherapy to extramedullary disease sites before CAR T therapy may improve PFS outcomes in multiple myeloma.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.